M&A Deal Summary

Danaher Acquires GE Biopharma

On February 25, 2019, Danaher acquired life science company GE Biopharma from GE Life Sciences for 21.4B USD

Acquisition Highlights
  • This is Danaher’s 5th transaction in the Life Science sector.
  • This is Danaher’s largest (disclosed) transaction.
  • This is Danaher’s 27th transaction in the United States.
  • This is Danaher’s 3rd transaction in Pennsylvania.

M&A Deal Summary
Date 2019-02-25
Target GE Biopharma
Sector Life Science
Buyer(s) Danaher
Sellers(s) GE Life Sciences
Deal Type Divestiture
Deal Value 21.4B USD
Advisor(s) PJT Partners, Inc.
J.P. Morgan Securities
Citigroup Investment Banking
Goldman Sachs (Financial)
Paul, Weiss, Rifkind, Wharton & Garrison (Legal)

Target

GE Biopharma

Pittsburgh, Pennsylvania, United States
GE Biopharma is a provider of instruments, consumables, and software that support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs. The business is comprised of process chromatography hardware and consumables, cell culture media, single-use technologies, development instrumentation and consumables, and service.

Search 200,577 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Danaher

Washington, District of Columbia, United States
Category Company
Founded 1969
Sector Diversified
Employees79,000
Revenue 23.9B USD (2023)
DESCRIPTION

Danaher designs, manufactures and markets professional, medical, industrial and commercial products and services. Danaher's research and development, manufacturing, sales, distribution, service and administrative facilities are located in more than 50 countries. Danaher's business consists of five segments: Test & Measurement; Environmental; Life Sciences & Diagnostics; Dental; and Industrial Technologies. Danaher was incorporated in 1969 and is based in Washington, District of Columbia.

DEAL STATS #
Overall 39 of 43
Sector (Life Science) 5 of 9
Type (Divestiture) 4 of 4
State (Pennsylvania) 3 of 3
Country (United States) 27 of 28
Year (2019) 1 of 1
Size (of disclosed) 1 of 23
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-03-09 Integrated DNA Technologies

Coralville, Iowa, United States

Integrated DNA Technologies, Inc. is a manufacturer of custom nucleic acids (i.e. building blocks of DNA and RNA) and assists researchers in advancing genomics technology, including synthetic biology and Next-Generation Sequencing. The company serves more than 80,000 customers across a diverse set of end markets including academic research, biotechnology, clinical diagnostics and pharmaceuticals.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-10-21 Danaher - Life Science Portfolio

Washington, District of Columbia, United States

Danaher Corp's Life Science Portfolio includes chromatography and SoloHill business. The chromatography business addresses an essential step in downstream bioprocessing and encompasses multi-use and single-use equipment as well as columns and resins. The SoloHill business includes mainly a microcarrier technology and particle validation standards used in cell culture and other bioprocesses.

Sell $750M

Seller(S) 1

SELLER

GE Life Sciences

Marlborough, Massachusetts, United States
Category Company
Sector Life Science
DESCRIPTION

GE Life Sciences offers solutions to support work from biological research to clinical therapy, including tools for research, drug discovery, diagnostics and bioprocessing. Ge Life Sciences is based in Marlborough, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal